KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Selling, General and Administrative Expenses

Last Annual Value

15.39M

3-Year CAGR

90%

5-Year CAGR

-7%

10-Year CAGR

-3%

KT

Kalaris Therapeutics Inc Competitors Analysis of Selling, General and Administrative Expenses

KLRS · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
15.39M
106.1%-20.7%N/A 
24.11M
-6.6%-8.3%6.4%
20.27M
13.4%9.5%N/A
17.23M
-3.7%-1.6%N/A
7.85M
2.5%16.6%N/A
26.79M
-2.4%22.5%N/A
63.12M
4.7%-0.4%10.0%
23.85M
-5.7%0.4%N/A
21.15M
N/A15.0%N/A
16.99M
10.3%8.4%N/A
8.72M
2.3%8.0%13.5%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66